spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Haloperidol 

 HSMN NewsFeed - 10 Jul 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 7 Dec 2016
Sobi and Horizon Pharma Enter Five-Year Distribution Agreement for Ravicti(R) and Ammonaps(R) Outside the United States
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2013
Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jul 2010
Shionogi Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2009
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2009
Hyperion Therapeutics Raises $60 Million Series C
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Apr 2008
Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jan 2008
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Vanda Presents Phase III Iloperidone Efficacy Data
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Haloperidol
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.